Search NLS News

Alligator Bioscience has announced the promotion of Laura von Schantz to Chief Technology Officer, and her joining the executive management team. In this role, she will oversee all technical aspects in the development of Alligator’s preclinical and clinical pipeline, including lead assets mitazalimab, a CD40 agonist currently in Phase 2 clinical development, and ATOR-1017, a […]

The European Health Data and Evidence Network (EHDEN) and Lundbeck have begun formative stages of neuroscience research with the EHDEN network and potential partners, including other pharma companies. Lundbeck joined the IMI EHDEN Consortium on 1st September 2022 and is now the first partner to join the neuroscience research programme. “This partnership will contribute to the neuroscience ecosystem […]

A new Norwegian clinical pilot will investigate how women can receive more personalized breast cancer screening. “This ‘one size fits all’ approach does not take into account the different breast cancer risks of individual women. A more personalised screening program might be beneficial for both women and society, both in terms of increased surveillance of […]

At Orion Pharma’s Fermion plant waste ethanol is used to reduce the nitrogen load in the Baltic Sea. Outside Hanko in Finland, two different plants are located side-by-side. One of them is Orion’s subsidiary Fermion, manufacturing pharmaceutical ingredients, and the other is the Dupont-owned Genencor International, manufacturing enzymes. The two plants decided to work together […]

The company has announced the completion of the patient enrollment in the company’s phase 3 clinical study SPARKLE with the lead candidate drug Orviglance. “We are very pleased to have reached our enrollment target of 80 patients in the SPARKLE study within our recently updated timelines. This is a major milestone in the history of […]

The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer. The MHLW approval is based on the positive results from the Phase III ARASENS trial, which demonstrated that darolutamide plus androgen deprivation therapy […]

The company has reported favorable safety and promising early signs of efficacy following an initial analysis of the phase Ib part of the clinical trial TRIFOUR. In collaboration with the Spanish Breast Cancer Group (GEICAM), this trial investigates the IL1RAP-binding antibody nadunolimab (CAN04) in combination with chemotherapy for treatment of triple-negative breast cancer (TNBC). In […]

Marcus Kaber was appointed Chief Executive Officer of the company on February 1. “We are excited to have Marcus as a part of our executive team. Our leadership team has vast knowledge of the pharmaceutical and medical industries, while Marcus brings a track record and experience in how to build successful software companies in an […]

Tony Hoos to replace Anders Ullman as Head of R&D and Medical Affairs and Chief Medical Officer from 1 April 2023. Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D. who will retire. Tony Hoos Dr Hoos brings more than […]

The companies have entered into a global exclusive license agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally. CMG901 CMG901 is currently being evaluated in a […]